Nephros Retained Earnings (Accumulated Deficit) 2010-2024 | NEPH
Nephros retained earnings (accumulated deficit) from 2010 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
| Nephros Annual Retained Earnings (Accumulated Deficit) (Millions of US $) |
|
|---|---|
| 2024 | $-144 |
| 2023 | $-144 |
| 2022 | $-143 |
| 2021 | $-136 |
| 2020 | $-132 |
| 2019 | $-127 |
| 2018 | $-124 |
| 2017 | $-121 |
| 2016 | $-120 |
| 2015 | $-117 |
| 2014 | $-114 |
| 2013 | $-107 |
| 2012 | $-98 |
| 2011 | $-94 |
| 2010 | $-92 |
| 2009 | $-90 |
| Nephros Quarterly Retained Earnings (Accumulated Deficit) (Millions of US $) |
|
|---|---|
| 2024-12-31 | $-144 |
| 2024-09-30 | $-145 |
| 2024-06-30 | $-145 |
| 2024-03-31 | $-145 |
| 2023-12-31 | $-144 |
| 2023-09-30 | $-144 |
| 2023-06-30 | $-144 |
| 2023-03-31 | $-143 |
| 2022-12-31 | $-143 |
| 2022-09-30 | $-142 |
| 2022-06-30 | $-139 |
| 2022-03-31 | $-138 |
| 2021-12-31 | $-136 |
| 2021-09-30 | $-135 |
| 2021-06-30 | $-134 |
| 2021-03-31 | $-132 |
| 2020-12-31 | $-132 |
| 2020-09-30 | $-131 |
| 2020-06-30 | $-130 |
| 2020-03-31 | $-128 |
| 2019-12-31 | $-127 |
| 2019-09-30 | $-127 |
| 2019-06-30 | $-126 |
| 2019-03-31 | $-126 |
| 2018-12-31 | $-124 |
| 2018-09-30 | $-123 |
| 2018-06-30 | $-123 |
| 2018-03-31 | $-122 |
| 2017-12-31 | $-121 |
| 2017-09-30 | $-122 |
| 2017-06-30 | $-122 |
| 2017-03-31 | $-121 |
| 2016-12-31 | $-120 |
| 2016-09-30 | $-120 |
| 2016-06-30 | $-119 |
| 2016-03-31 | $-118 |
| 2015-12-31 | $-117 |
| 2015-09-30 | $-116 |
| 2015-06-30 | $-116 |
| 2015-03-31 | $-114 |
| 2014-12-31 | $-114 |
| 2014-09-30 | $-103 |
| 2014-06-30 | $-103 |
| 2014-03-31 | $-102 |
| 2013-12-31 | $-107 |
| 2013-09-30 | $-100 |
| 2013-06-30 | $-99 |
| 2013-03-31 | $-99 |
| 2012-12-31 | $-98 |
| 2012-09-30 | $-96 |
| 2012-06-30 | $-96 |
| 2012-03-31 | $-95 |
| 2011-12-31 | $-94 |
| 2011-09-30 | $-94 |
| 2011-06-30 | $-93 |
| 2011-03-31 | $-93 |
| 2010-12-31 | $-92 |
| 2010-09-30 | $-91 |
| 2010-06-30 | $-91 |
| 2010-03-31 | $-91 |
| 2009-12-31 | $-90 |
| 2009-09-30 | |
| 2009-06-30 | |
| 2009-03-31 | $-89 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.021B | $0.014B |
| Nephros develops advanced End Stage Renal Disease, or ESRD, therapy technology and products that would address both patient treatment needs and the clinical and financial needs of the treatment provider. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $233.051B | 28.02 |
| Boston Scientific (BSX) | United States | $155.046B | 38.81 |
| Stryker (SYK) | United States | $146.591B | 30.65 |
| EssilorLuxottica (ESLOY) | France | $128.427B | 0.00 |
| Medtronic (MDT) | Ireland | $106.656B | 15.57 |
| Lonza Group Ag (LZAGY) | Switzerland | $50.804B | 0.00 |
| Haleon (HLN) | United Kingdom | $48.530B | 27.59 |
| ResMed (RMD) | United States | $35.880B | 26.95 |
| GE HealthCare Technologies (GEHC) | United States | $31.512B | 14.96 |
| Agilent Technologies (A) | United States | $30.654B | 20.25 |
| Terumo (TRUMY) | Japan | $28.279B | 0.00 |
| Koninklijke Philips (PHG) | Netherlands | $22.455B | 16.14 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.623B | 11.96 |
| Insulet (PODD) | United States | $18.597B | 79.37 |
| Baxter (BAX) | United States | $15.765B | 11.77 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $12.408B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $9.032B | 0.00 |
| Demant (WILYY) | Denmark | $7.910B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $6.514B | 22.02 |
| Lantheus Holdings (LNTH) | United States | $5.512B | 14.05 |
| Prestige Consumer Healthcare (PBH) | United States | $4.033B | 19.25 |
| Perrigo (PRGO) | Ireland | $3.604B | 9.20 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| ICU Medical (ICUI) | United States | $3.310B | 28.20 |
| Haemonetics (HAE) | United States | $3.228B | 15.19 |
| Envista Holdings (NVST) | United States | $2.854B | 23.72 |
| GN Store Nord (GNNDY) | Denmark | $2.010B | 16.65 |
| LeMaitre Vascular (LMAT) | United States | $1.844B | 41.21 |
| QuidelOrtho (QDEL) | United States | $1.744B | 12.02 |
| AtriCure (ATRC) | United States | $1.500B | 0.00 |
| Neogen (NEOG) | United States | $1.287B | 16.47 |
| Green Thumb Industries (GTBIF) | United States | $1.274B | 28.67 |
| Kestra Medical Technologies (KMTS) | United States | $1.121B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.111B | 11.28 |
| BioLife Solutions (BLFS) | United States | $1.014B | 0.00 |
| InMode (INMD) | Israel | $0.989B | 9.06 |
| Phibro Animal Health (PAHC) | United States | $0.785B | 10.05 |
| Evolus (EOLS) | United States | $0.758B | 0.00 |
| Owens & Minor (OMI) | United States | $0.599B | 5.11 |
| CeriBell (CBLL) | United States | $0.577B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.565B | 0.00 |
| Valneva SE (VALN) | France | $0.551B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.539B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.435B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.411B | 0.00 |
| Surmodics (SRDX) | United States | $0.388B | 0.00 |
| Omeros (OMER) | United States | $0.370B | 0.00 |
| SNDL (SNDL) | Canada | $0.342B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.337B | 14.59 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.317B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.315B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.287B | 24.23 |
| Verano Holdings (VRNOF) | United States | $0.287B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.283B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.270B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.258B | 45.90 |
| Cerus (CERS) | United States | $0.249B | 0.00 |
| ZimVie (ZIMV) | United States | $0.248B | 14.83 |
| Canopy Growth (CGC) | Canada | $0.237B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.216B | 0.00 |
| Quanterix (QTRX) | United States | $0.208B | 0.00 |
| High Tide (HITI) | Canada | $0.192B | 0.00 |
| Biote (BTMD) | United States | $0.183B | 5.14 |
| Utah Medical Products (UTMD) | United States | $0.177B | 14.27 |
| TriSalus Life Sciences (TLSI) | United States | $0.168B | 0.00 |
| Brainsway (BWAY) | Israel | $0.164B | 51.24 |
| Organigram Global (OGI) | Canada | $0.150B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.149B | 18.39 |
| Jin Medical (ZJYL) | China | $0.126B | 0.00 |
| Exagen (XGN) | United States | $0.123B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.116B | 0.00 |
| MacroGenics (MGNX) | United States | $0.094B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.092B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.091B | 0.00 |
| Agape ATP (ATPC) | $0.086B | 0.00 | |
| Jushi Holdings (JUSHF) | United States | $0.083B | 0.00 |
| Fonar (FONR) | United States | $0.076B | 10.70 |
| Veru (VERU) | United States | $0.073B | 0.00 |
| InterCure (INCR) | Israel | $0.073B | 0.00 |
| Zynex (ZYXI) | United States | $0.063B | 0.00 |
| United Health Products (UEEC) | United States | $0.058B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.055B | 0.00 |
| Apyx Medical (APYX) | United States | $0.047B | 0.00 |
| ImmuCell (ICCC) | United States | $0.047B | 0.00 |
| Modular Medical (MODD) | United States | $0.042B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.038B | 56.00 |
| Safety Shot (SHOT) | United States | $0.037B | 0.00 |
| United-Guardian (UG) | United States | $0.037B | 11.24 |
| INLIF (INLF) | $0.016B | 0.00 | |
| Trinity Biotech (TRIB) | Ireland | $0.014B | 0.00 |
| Flora Growth (FLGC) | United States | $0.012B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.011B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.011B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.007B | 0.00 |
| Senestech (SNES) | United States | $0.005B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.004B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.004B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |